An integrated humoral and cellular response is elicited in pancreatic cancer by alpha-enolase, a novel pancreatic ductal adenocarcinoma-associated antigen.

@article{Cappello2009AnIH,
  title={An integrated humoral and cellular response is elicited in pancreatic cancer by alpha-enolase, a novel pancreatic ductal adenocarcinoma-associated antigen.},
  author={Paola Cappello and Barbara Tomaino and Roberto Chiarle and Patrizia Ceruti and Anna Maria Teresa Novarino and Carlotta Castagnoli and Paola Migliorini and Giovanni Perconti and Agata Giallongo and Michele Milella and Vladia Monsurr{\'o} and Stefano Barbi and Aldo Scarpa and Paola Nistic{\`o} and Mirella Giovarelli and Francesco Novelli},
  journal={International journal of cancer},
  year={2009},
  volume={125 3},
  pages={639-48}
}
Pancreatic ductal adenocarcinoma (PDAC) is a fatal disease with a very poor 5-year survival rate. alpha-Enolase is a glycolytic enzyme that also acts as a surface plasminogen receptor. We find that it is overexpressed in PDAC and present on the cell surface of PDAC cell lines. The clinical correlation of its expression with tumor status has been reported for lung and hepatocellular carcinoma. We have previously demonstrated that sera from PDAC patients contain IgG autoantibodies to alpha… CONTINUE READING